Key Highlights
- On March 31, 2026, ARK Invest acquired approximately $240 million in OpenAI Group shares distributed among three exchange-traded funds
- The same day, OpenAI completed a record-breaking $122 billion funding round, establishing an $852 billion company valuation
- ARK’s portfolio additions included CoreWeave and DoorDash stock purchases
- The investment firm divested more than 600,000 Strata Critical Medical shares while reducing holdings in Veracyte and Teradyne
- This marks the first time retail investors can gain indirect exposure to OpenAI through publicly traded ETFs managed by ARK
Cathie Wood’s investment management firm, ARK Invest, executed one of its most substantial transactions on March 31, 2026, allocating approximately $240 million to acquire OpenAI Group stock distributed among three exchange-traded funds.
The investment was distributed among the ARK Innovation ETF, ARK Next Generation Internet ETF, and ARK Blockchain and Fintech Innovation ETF. Following this transaction, each fund maintains approximately 3% ownership in OpenAI Group PBC, Series C.
Prior to this transaction, OpenAI shares were exclusively held within ARK’s closed-end Venture Fund. That particular fund initially invested during 2024 and subsequently contributed an additional $250 million investment in October of the same year.
ARK’s strategic investment coincided with a significant capital announcement from OpenAI. The artificial intelligence company finalized its most substantial funding round to date at $122 billion on the identical day, elevating its corporate valuation to $852 billion.
According to OpenAI’s statement, the capital infusion will be allocated toward semiconductor purchases, data center infrastructure expansion, and workforce growth. The organization additionally facilitated approximately $3 billion in direct share sales to individual investors through a private placement coordinated with three prominent financial institutions.
Sarah Friar, OpenAI’s Chief Financial Officer, emphasized the company’s commitment to providing retail investors with access not only to its technological innovations but also to the potential financial returns associated with ownership.
How ARK’s OpenAI Investment Benefits Everyday Investors
By incorporating OpenAI shares into publicly accessible ETFs, ARK Invest has created a pathway for ordinary investors to obtain exposure to a privately held enterprise. This approach is remarkable, as most retail market participants typically cannot purchase private company equity before it goes public through an initial public offering.
However, there are considerations regarding valuation. While ETFs maintain continuous trading throughout market hours, privately held company shares lack real-time pricing mechanisms. Portfolio managers must utilize estimated valuations for these holdings and may need to liquidate more liquid positions to accommodate shareholder redemption requests.
Cathie Wood addressed the investment decision, stating that within the fintech ecosystem, agentic artificial intelligence will generate extraordinary opportunities.
Additional ARK Portfolio Transactions on March 31
In addition to the OpenAI acquisition, ARK purchased 26,515 shares of CoreWeave, a cloud computing infrastructure provider, valued at approximately $2.05 million. CoreWeave’s stock price increased 12% during that trading session.
ARK also expanded its position in DoorDash, acquiring 14,729 shares worth $2.21 million. This purchase followed a previous DoorDash transaction the prior day, strengthening ARK’s exposure to the food delivery industry.
Regarding portfolio reductions, ARK liquidated 612,483 shares of Strata Critical Medical, generating $2.56 million in proceeds. The healthcare company specializes in delivering urgent logistics and medical support services to healthcare facilities throughout the United States.
ARK additionally divested 6,204 Teradyne shares valued at $1.84 million and sold 115,718 Veracyte shares across its ARKK and ARKG exchange-traded funds, totaling $3.52 million. ARK had been systematically decreasing its Veracyte allocation throughout the preceding week.
The OpenAI financing round concluded with an $852 billion valuation on March 31, 2026, precisely when ARK executed its $240 million acquisition across its three primary ETF vehicles.
